Lawmakers Press FDA for Documents Relating to Controversial Opioid Approval

Drug Industry Daily
A A
Congressional Democrats are calling on the FDA to answer “substantive questions” surrounding the agency’s approval of Dsuvia, AcelRx’s sublingual formulation of the powerful opioid sufentanil.

To View This Article:

Login

Subscribe To Drug Industry Daily